Bayer gains cancer drug from China's Puhe; Axsome gets mixed ADHD data [Yahoo! Finance]
Axsome Therapeutics, Inc. (AXSM)
Last axsome therapeutics, inc. earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
axsome.com
Company Research
Source: Yahoo! Finance
Today, a brief rundown of news involving Bayer and Axsome Therapeutics, as well as updates from GSK, Novo Nordisk and Augustine Therapeutics that you may have missed. Bayer is adding to its cancer drug pipeline via a deal with China-based Suzhou Puhe BioPharma , securing a worldwide license to a small molecule medicine that's just begun Phase 1 testing. The medicine, now dubbed BAY 3713372 , blocks an enzyme known as PRMT5 that is thought to play a role in the cell cycle. Bayer will develop it for tumors that have deletions in a gene called MTAP, which is estimated to occur in 10% to 30% of all cancers, according to research cited by the company. Other developers, including Amgen , are working on PRMT5 inhibitors, too. — Ned Pagliarulo
Read more
Impact Snapshot
Event Time:
AXSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXSM alerts
High impacting Axsome Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AXSM
News
- Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Mizuho from $212.00 to $216.00. They now have an "outperform" rating on the stock.MarketBeat
- IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried. [Yahoo! Finance]Yahoo! Finance
- Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint [Yahoo! Finance]Yahoo! Finance
- Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary EndpointGlobeNewswire
- Acetylcholine Receptor Antagonists Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight [Yahoo! Finance]Yahoo! Finance
AXSM
Earnings
- 2/18/25 - Miss
AXSM
Sec Filings
- 3/25/25 - Form 8-K
- 3/5/25 - Form 8-K
- 3/3/25 - Form 8-K
- AXSM's page on the SEC website